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Key Points Summary 
 
 We sought to determine the isolated and combined influence of hypovolemia and 
hypoxic pulmonary vasoconstriction on the decrease in left ventricular (LV) function 
and maximal exercise capacity observed under hypobaric hypoxia.  
 We performed echocardiography and maximal exercise tests at sea level (344m), and 
following 5-10 days at the Barcroft Laboratory (3800m; White Mountain, California) 
with and without (i) plasma volume expansion to sea level values and (ii) 
administration of the pulmonary vasodilator Sildenafil in a double-blinded and placebo-
controlled trial.  
 The high altitude-induced reduction in LV filling and ejection was abolished by plasma 
volume expansion but to a lesser extent by sildenafil administration; however, neither 
intervention had a positive effect on maximal exercise capacity.  
 Both hypovolemia and hypoxic pulmonary vasoconstriction play a role in the reduction 
of LV filling at 3800 m, but the increase in LV filling does not influence exercise capacity 
at this moderate altitude.   
 
  
Abstract 
 
We aimed to determine the isolated and combined contribution of hypovolemia and hypoxic 
pulmonary vasoconstriction in limiting left ventricular (LV) function and exercise capacity 
under chronic hypoxemia at high altitude. In a double-blinded, randomized and placebo-
controlled design, twelve healthy participants underwent echocardiography at rest and during 
submaximal exercise before completing a maximal test to exhaustion at sea level (SL; 344 m) 
and after 5-10 days at 3800 m. Plasma volume was normalised to SL values, and hypoxic 
pulmonary vasoconstriction was reversed by administration of Sildenafil (50 mg) to create four 
unique experimental conditions that were compared with SL values; high altitude (HA), Plasma 
Volume Expansion (HA-PVX), Sildenafil (HA-SIL) and Plasma Volume Expansion with Sildenafil 
(HA-PVX-SIL). High altitude exposure reduced plasma volume by 11% (P<0.01) and increased 
pulmonary artery systolic pressure (19.6  4.3 vs. 26.0  5.4, P<0.001); these differences were 
abolished by PVX and SIL respectively. LV end-diastolic volume (EDV) and stroke volume (SV) 
were decreased upon ascent to high altitude, but were comparable to sea level in the HA-PVX. 
LV EDV and SV were also elevated in the HA-SIL and HA-PVX-SIL trials compared to HA, but to a 
lesser extent. Neither PVX or SIL had a significant effect on the LV EDV and SV response to 
exercise, or the maximal oxygen consumption or peak power output. In summary, at 3800 m 
both hypovolemia and hypoxic pulmonary vasoconstriction contribute to the decrease in LV 
filling, however, restoring LV filling does not confer an improvement in maximal exercise 
performance.  
 
 
 
 
 
 
 
  
Introduction 
 
Following acclimatisation to high altitude, cardiac output at rest and during exercise is 
comparable to sea level, but is achieved through an increased heart rate and a lower stoke 
volume (Sutton et al., 1988). The reduction in stroke volume is accompanied by a decrease in 
left ventricular (LV) filling (Alexander & Grover, 1983; Boussuges et al., 2000; Stembridge et al., 
2015). Two mechanisms have been proposed to explain this reduction in stroke volume: (i) 
decreased blood volume (Alexander et al., 1967; Grover et al., 1976) and (ii) increased 
pulmonary vascular resistance (Allemann et al., 2004; Naeije et al., 2010). A reduction in plasma 
volume with acclimatisation to high altitude has been consistently reported in the literature 
over the last 50 years (Pugh, 1964; Alexander et al., 1967; Robach et al., 2000; Ryan et al., 2014), 
but there is no consensus as to whether the decrease in LV filling is a direct consequence of 
hypovolemia. For example, Alexander et al. (1967) observed a reduction in both blood volume 
and directly measured ventricular filling pressures, but a Dextran infusion only restored stroke 
volume in one of the two subjects tested despite the restoration in right atrial pressure in both. 
Moreover, Calbet et al. (2004) reported no change in stroke volume and an increase in heart 
rate following plasma volume expansion after 9 weeks at 5,260 m. In contrast, Grover et al. 
(1976) demonstrated a maintained stroke volume during acclimatisation when subjects (n=5) 
were kept isovolemic by preventing alkalosis via CO2 supplementation, and Siebenmann et al. 
(2013) restored stroke volume (as estimated by pulse contour analysis) following 
normalisation of plasma volume via Dextran infusion.  
 
The second candidate mechanism for the lower LV filling at high altitude is the increase in 
pulmonary vascular resistance secondary to hypoxic pulmonary vasoconstriction. In response 
to hypoxia, the pulmonary vasculature constricts and creates a greater load against which the 
right ventricle (RV) must contract (Naeije & Dedobbeleer, 2013). During acute hypoxia, 
pulmonary pressure is increased, RV systolic function is elevated and LV end-diastolic volume 
(EDV) is maintained. Following acclimatisation, pulmonary pressure remains elevated but RV 
systolic function is slightly decreased (Stembridge et al., 2014) and LV EDV is lower. Indeed, 
pulmonary artery systolic pressure has been shown to be inversely related to LV diastolic filling 
at high altitude (Allemann et al., 2004). 
 
Changes in plasma volume and pulmonary vascular resistance in response to hypoxia have also 
been investigated as potential limiting factors to maximal exercise performance at high altitude. 
Pharmacological reversal of hypoxic pulmonary vasoconstriction has been shown in multiple 
studies to improve maximal exercise performance in acute and chronic hypoxia (Ghofrani et al., 
2004; Faoro et al., 2009; Naeije et al., 2010). Plasma volume expansion has been show to 
improve VO2 max at high altitude (Robach et al., 2000), although this is not a consistent finding 
(Calbet et al., 2004). Theoretical analysis has demonstrated that the importance of cardiac 
output in oxygen transport diminishes with increasing altitude, such that on the summit of 
Mount Everest (Pb= 253 Torr), VO2 max is independent of maximal cardiac output (Wagner, 
1996). However, at moderate altitudes, any improvement in maximal exercise performance 
with either plasma volume expansion or pulmonary vasodilation may be underpinned by 
changes in cardiac function that are evident during submaximal intensities (Hsu et al., 2006; 
Kjaergaard et al., 2007). Importantly though, both interventions may alter arterial oxygen 
content at maximal exercise via either hemodilution with plasma volume expansion (Duke et al., 
2016), or increased diffusion limitation with shorter pulmonary transit times (Wagner, 1996).  
 
Collectively, the available evidence suggests that changes in blood volume and pulmonary 
vascular resistance and may affect stroke volume and exercise capacity at high altitude either 
independently or in combination, however this remains to be experimentally determined. The 
aims of this study are therefore fourfold: determine the independent and combined effect of 
high altitude-induced (1) hypovolemia and (2) hypoxic pulmonary vasoconstriction on LV filling 
and the resultant changes in ventricular function, (3) examine how hypovolemia and hypoxic 
pulmonary vasoconstriction influence the left and right ventricular response to submaximal 
exercise and (4) explore the potential role of plasma volume normalisation and the reversal of 
pulmonary vasoconstriction to improve maximal exercise at high altitude. We hypothesised that 
(1) both plasma volume normalisation and (2) reversal of hypoxic pulmonary vasoconstriction 
would increase LV filling at rest and (3) these responses would be evident during exercise, but 
(4) only the reversal of hypoxic pulmonary vasoconstriction would increase maximal exercise 
performance. 
 
 
 
  
Methods 
 
Ethical Approval 
Ethical approval was granted by the Clinical Research Ethics Board at the University of British 
Columbia and conformed to the Declaration of Helsinki, except for registration in a database. 
Written informed consent was obtained from all volunteers prior to participation in the study. 
The current study was a standalone experiment that formed part of a high altitude expedition to 
the Barcroft Research Station (White Mountain, California, USA; 3800 m). As such, the 
participants took part in a number of investigations, however care was taken to ensure no 
overlap existed between any of the studies performed, and each study addressed a distinct a 
priori research question.  
 
Participants 
Twelve male participants (aged 27  6, height 178  4 cm and weight 73  7 kg) were recruited 
from the expedition team who were normotensive, non-smokers with no previous history of 
cardiovascular or respiratory diseases and were taking no prescription medications. Lung 
function, lung volume and lung diffusing capacity were assessed at baseline in accordance with 
the American Thoracic Society and European Respiratory Society’s joint guidelines (Macintyre 
et al., 2005; Miller et al., 2005) as previously reported by our group (Tymko et al., 2017). The 
participants completed baseline trials at sea level (Kelowna, British Columbia; 344 m) before 
travelling to California and ascending to 3800 m over the course of 9-10 hours by motor vehicle. 
The high altitude phase of testing was performed between days 5 and 10 after arrival at 3800 m. 
None of the participants were experiencing any symptoms of acute mountain sickness, as 
assessed by the Lake Louise questionnaire.   
 
Experimental Design 
The two phases of testing required three laboratory visits at sea level and three visits at high 
altitude. Prior to each visit, participants were asked to abstain from exercise, alcohol and 
caffeine for at least 12 hours. The experimental design allowed the examination of cardiac 
function at rest and during exercise, at sea level (SL) and high altitude (HA) with and without 
the administration of the pulmonary vasodilator Sildenafil (SIL), before and after plasma 
volume expansion (PVX) to return plasma volume to sea level values. This generated five 
experimental conditions: Sea Level (SL), High Altitude (HA), High Altitude with Plasma Volume 
Expansion (HA-PVX), High Altitude with Sildenafil (HA-SIL) and High Altitude with both Plasma 
Volume Expansion and Sildenafil (HA-PVX-SIL). In addition, maximal aerobic capacity was 
assessed in four conditions:  Sea Level (SL), High Altitude (HA) and High Altitude with both 
Plasma Volume Expansion (HA-PVX) and Sildenafil (HA-PVX-SIL). An overview of the 
experimental design is illustrated in Figure 1.  
 
Sea level experimental visits 
At sea level, participants completed an incremental test to exhaustion on a semi-recumbent 
exercise ergometer (Lode Angio, Lode, Groningen, the Netherlands; see ‘Experimental Protocols’ 
below for full details). The aim of this test was to establish each individual’s peak power so that 
relative intensities could be prescribed in the subsequent visits. All exercise echocardiograms at 
sea level and high altitude were performed at 50% of the power achieved during this visit in the 
semi-recumbent position. During the second visit, echocardiography was performed during rest 
and at 50% peak power. After 30 minutes rest, the participants then completed another 
incremental test to exhaustion to assess maximal oxygen consumption. The following day, the 
participants returned to the laboratory for the measurement of absolute blood volume via the 
carbon monoxide rebreathing method described below. Absolute blood volume was used to 
calculate the volume of fluid that was required to restore plasma volume in visits 2 and 3 at high 
altitude.  
 
High altitude experimental visits 
To maintain consistency between sea level and high altitude testing, the same equipment was 
driven from Kelowna, Canada to The Barcroft Laboratory, USA including the ultrasound 
machine and the exercise ergometer. During high altitude testing, an electrical fault developed 
in our cycle ergometer, so this was replaced by a second electronically-braked ergometer from 
the same manufacturer. Given that the order of visits were randomized, we are confident any 
differences between devices would be accounted for by our experimental design. At high 
altitude, the order of experimental visits was randomised to avoid any order effect due to 
acclimatisation. Before all trials, haemoglobin (Hb) concentration (Hemocue, Radiometer, 
Copenhagen, Denmark) and haematocrit (HCT; microhaematocrit centrifugation technique) 
were assessed from a blood sample taken from an indwelling catheter placed in the antecubital 
vein in order to calculate the percentage change in blood volume from sea level (Dill & Costill, 
1974). In visits 2 and 3, the percentage change and the absolute plasma volume from sea level 
was used to generate a target infusion volume for each individual. Sildenafil was administered 
orally (50mg) in a randomised and double-blinded approach.  
 
During the high altitude visit 1, participants completed a VO2 peak test that was used to 
determine the change in aerobic capacity from sea level. Visits 2 and 3 were identical, apart 
from the study clinician administering either 50mg Sildenafil or placebo 60 minutes prior to 
commencing testing. All experimenters and participants were blinded to the conditions except 
the study clinician (JA). The participants underwent an echocardiogram during rest and at 50% 
peak power. The required target volume of Saline was then infused over the course of 20-40 
minutes by infusion pump (Carefusion, San Diego, CA, USA) and Hb and HCT were reassessed to 
check plasma volume expansion to sea level values had been achieved. The volume required to 
restore plasma volume in each condition is reported in the results. This was followed by 
repeating the rest and exercise echocardiogram. A 30-minute rest period then preceded the VO2 
peak test.  
 
Experimental Protocols 
Incremental test to exhaustion (VO2 Peak Test): The incremental exercise test was 
performed in the semi-recumbent position on an electronically-braked cycle ergometer (Lode 
Angio, Lode, Groningen, the Netherlands). Participants were instructed to keep their cadence 
between 70-80 rpm throughout the test. Following a two-minute warm up at 100 W, 20 W was 
added every minute until volitional exhaustion. Where the test was terminated midway through 
a stage, the 20 W increment was divided by 60, multiplied by the time completed and added to 
the power output from the last complete stage. During the incremental tests, ventilation (VE), O2 
uptake (VO2) and CO2 production (VCO2) were assessed via breath-by-breath online gas analysis 
(Oxycon Mobile, Carefusion, San Diego, CA, USA), as previously used at high altitude (Faoro et 
al., 2013). In addition to respiratory analysis, heart rate was recorded via a 3-lead 
electrocardiogram and peripheral oxygen saturation (SpO2) via finger pulse oximetry.  
 
Rest and exercise echocardiogram: Echocardiographic images were obtained with the 
participants resting or cycling in the left lateral decubitus position, by the same sonographer 
(MS), using a commercially available ultrasound system (Vivid E9, GE Healthcare, Piscataway, 
NJ, USA). All images were acquired at end-expiration. Exercise images were obtained after two 
minutes of cycling to allow the participant to reach steady state, and were completed within five 
minutes.  
 
Parasternal long- and short-axis views and apical four and two chamber views were recorded 
for three consecutive cycles and stored for offline analysis (Echopac, GE Healthcare, Piscataway, 
NJ, USA). Left ventricular volumes were assessed from apical four and two chamber images in 
accordance with the American Society of Echocardiography guidelines (Lang et al., 2015). 
Transmitral early (E) and atrial (A) filling was assessed via pulsed-wave Doppler recordings 
from an apical four chamber view, with the sample volume placed between the tips of the mitral 
valve leaflets. Right ventricular areas were assessed from a modified apical 4 chamber view in 
line with the RV American Society of Echocardiography guidelines for the assessment of the 
right heart (Rudski et al., 2010). Pulmonary artery systolic pressure (PASP) was quantified as 
the maximum systolic pressure gradient across the tricuspid valve added to right atrial pressure 
estimated from the collapsibility of the inferior vena cava. To derive pressure, the modified 
Bernoulli equation (4V2) was applied to the peak systolic regurgitation jet velocity measured via 
continuous wave Doppler. Unfortunately, due to the difficulty in identifying the regurgitant jet 
during exercise with a higher ventilation at high altitude, it could only be achieved in 26% of 
time points during exercise. The missing data meant from our n=12, we only acquired PASP 
data in n=3 across all time points. For this reason, PASP data during exercise is not reported. At 
rest, pulmonary vascular resistance was estimated from the ratio of the tricuspid regurgitant jet 
velocity to the velocity-time integral obtained in the right ventricular outflow tract in a 
parasternal short-axis view (Rudski et al., 2010). Pulmonary vascular resistance (PVR) was 
estimated from the ratio of the tricuspid regurgitant jet velocity to the velocity-time integral 
obtained in the right ventricular outflow tract in a parasternal short-axis view (Abbas et al., 
2003; Rudski et al., 2010).  
 
Left and right ventricular mechanics were assessed via two-dimensional speckle-tracking 
echocardiography. LV circumferential strain, rotation, strain rate and rotation velocity were 
measured from parasternal short-axis views at the base and apex, as previously described in 
detail (Stembridge et al., 2014). LV twist, systolic twist velocity and untwisting velocity were 
calculated by subtracting the apical frame-by-frame data from the basal data. Left and right 
ventricular longitudinal strain and strain rate were analysed from apical four chamber views. 
All images for speckle-tracking analysis were obtained at the highest possible frame rates (> 70 
frames per second) and kept consistent within individuals. Intra-observer coefficient of 
variation for the study sonographer (MS) have been reported previously (Stembridge et al., 
2015), and range from 8.1-11% for speckle-tracking imaging.  
 
Absolute blood volume: Blood volume was assessed at sea level using the carbon monoxide 
rebreathing method (Schmidt & Prommer, 2005), as previously used at high altitude (Ryan et 
al., 2014). The participants were instructed to inhale maximally from a custom-made glass 
spirometer (Bloodtec, GbR, Germany) attached to a 5 L reservoir bag containing 100% O2 whilst 
carbon monoxide was added (1.0 ml kg-1). The participants then held the full inspiration for 10 
seconds before breathing in and out of the spirometer for two minutes. At the end of the two 
minutes, the participants exhaled fully into the spirometer before returning to room air. Venous 
blood samples were taken before and after the rebreathing for the assessment of Hb 
concentration, HCT and the percentage of Hb bound to carbon monoxide (HbCO; ABL 90, 
Radiometer, Denmark). Exhaled carbon monoxide was measured using a portable carbon 
monoxide device (Dräger Pac 3500, Daeger Safety Inc., Texas, USA) at baseline, 4-minutes post 
and 7-minutes post rebreathe.  
 
Statistical Analyses 
Results are presented as means  standard deviation (SD), and each participant has their own 
unique symbol across Figures 2-4 so that individual responses can be tracked between 
experimental conditions. Our four hypotheses stated in the introduction were approached using 
the following statistical methods. To explore the effect of the (1) hypovolemia and (2) hypoxic 
pulmonary vasoconstriction at rest, two separate repeated measures one-way analysis of 
variance (ANOVA) were run with paired-samples t tests used to detect differences where there 
was a significant main effect; (3) to explore the response to exercise during the different 
conditions, a two-way repeated measures ANOVA was used (condition and exercise intensity) 
with paired-samples t tests used to detect differences where there was a significant main effect 
and (4) to examine the differences in maximal exercise performance, a one-way repeated 
measures ANOVA was employed with paired-samples t tests used to detect differences where 
there was a significant main effect. A Bonferroni correction was applied to all post hoc t tests to 
account for multiple comparisons, with adjusted p values reported. To determine whether 
meaningful differences were present, effect sizes (Cohen’s d) are reported. Data were normally 
distributed, as confirmed via Shapiro-Wilk normality test. Where sphericity could not be 
assumed (Mauchly’s) the Greenhouse-Geisser correction was applied.  
 
  
Results 
 
Effectiveness of interventions 
The haematological and pulmonary vascular changes following the interventions are shown in 
Table 1. Plasma volume was decreased at high altitude by 11  7% and 12  7% in the HA and 
HA-SIL trials, respectively. Following the infusion in the HA-PVX and HA-PVX-SIL trials, plasma 
volume was comparable to sea level. The average infusion volume required to restore plasma 
volume was 398  248 ml in the HA-PVX trial and 438  247 ml in the HA-PVX-SIL trial. PASP 
and PVR were both elevated in the placebo trials at high altitude (HA and HA-PVX); however, 
Sildenafil was effective in reversing this response as there was no significant difference in either 
PASP or PVR in the Sildenafil trials (HA-SIL and HA-PVX-SIL) when compared to sea level.  
  
Effects of plasma volume expansion and Sildenafil administration on left ventricular filling and 
ejection at rest 
 
LV EDV and SV were reduced in the HA condition in comparison to SL (Figure 2). In addition, 
there was also a decrease in transmitral E velocity and E/A ratio and an increase in LV twist, 
apical rotation and apical circumferential strain rate (Table 2). Although there was a significant 
main effect for right ventricular end-diastolic (P=0.045) and end-systolic area (P=0.038), post-
hoc tests failed to reach significance (P=0.085 and P=0.054, respectively). The reduction in LV 
EDV and SV from sea level to high altitude was abolished after HA-PVX, and transmitral E 
(P=0.142) velocity and E/A ratio (P=0.524) were no longer significantly decreased; however, LV 
twist and apical circumferential strain rate remained elevated (Table 2).  
 
In the Sildenafil conditions, LV EDV (P=0.132) and SV (P=0.092) were not different to sea level 
values. However, the probability values suggest a trend for SV to be lower, as do post hoc tests 
between SL and HA-SIL (P=0.060). However, this was not the case for HA-PVX-SIL (P=0.471). To 
explore whether there was a non-significant but meaningful change between SL and HA-SIL, 
effect sizes were calculated and, for completeness, reported for all conditions (Figure 2). The 
greatest effect size between SL and the altitude conditions for LV EDV and SV were seen in the 
HA condition (Cohen’s d=0.874 and 0.729, respectively). The effect sizes for LV EDV and SV 
were indicative of a small effect for the HA-PVX condition (Cohen’s d= 0.0.018 and 0.363, 
respectively), suggesting plasma volume expansion was effective at altering LV EDV and SV. In 
the Sildenafil trials, effect sizes were larger (Cohen’s d= 0.408 and 0.523 for LV EDV and SV, 
respectively) suggesting a meaningful difference remained despite no significant difference 
being apparent from difference testing.  In the HA-PVX-SIL condition, effect sizes were smaller 
than HA-SIL but not as small as HA-PVX (Cohen’s d= 0.273 and 0.292 for LV EDV and SV, 
respectively).  
 
The influence of plasma volume expansion and Sildenafil administration on the left ventricular 
response to exercise 
 
LV EDV did not increase from rest to exercise in either the placebo (main effect for exercise 
P=0.300) or Sildenafil (main effect for exercise P=0.889) trials (Figure 3). In contrast, both 
placebo and Sildenafil trials demonstrated an increase in stroke volume from rest to exercise, 
with post hoc differences evident in the SL and HA trials. When the main effect for condition is 
considered (pooled rest and exercise data), LV EDV was lower compared to SL in the HA, HA-SIL 
and HA-PVX-SIL conditions indicating that LV EDV was most comparable to sea level during the 
HA-PVX trial.  
 
 
Maximal exercise 
Peak power was significantly lower during all three high altitude conditions (HA, HA-PVX and 
HA-PVX-SIL) in comparison to sea level (P<0.001; Figure 4); however, there were no differences 
between the reductions in peak power in the high altitude trials. Differences in VO2 peak 
between SL and HA conditions did not reach statistical significance (ANOVA P=0.091).  
 
 
 
  
Discussion 
 
In relation to our four hypothesises, we report the following principle findings: (1) at 3800 m, 
normalisation of plasma volume to sea level values restores LV EDV and SV at rest and (2) the 
reversal of hypoxic pulmonary vasoconstriction appears to also influence LV EDV in a similar 
manner, but to a lesser extent; (3) neither plasma volume expansion or Sildenafil 
administration altered the LV EDV and SV response to exercise; and (4) neither the restoration 
of plasma volume or the reduction of pulmonary vascular resistance ameliorated the reduction 
in maximal exercise capacity at 3800 m.  
 
Left ventricular filling at high altitude 
  
Alexander and Grover (1983) first proposed that the decline in LV filling upon ascent to high 
altitude was a consequence of the reduction in plasma volume that occurs after the first 3-5 
days above 3000 m. The current study demonstrates that normalising plasma volume to sea 
level values does indeed restore LV end-diastolic volume and stroke volume. This is in contrast 
to the previous study of Calbet et al. (2004) who reported no change in stroke volume when 
participants were made hypervolemic (via infusion of 1L Dextran solution) at high altitude, but 
in agreement with the more recent work of Siebenmann et al. (2013) who concluded that the 
reduction in stroke volume can be exclusively explained by the decrease in plasma volume. The 
differential finding between the work of Calbet et al. (2004) with that of Siebenmann et al. 
(2013) and ourselves may be explained by important distinctions in the methodological 
approach. First, the length of exposure varies greatly between the three studies with relatively 
short durations of ours (5-10 days) and Siebenmann et al. (2013) (26 days), compared to 9 
weeks in the study by Calbet et al. (2004). Second, and most importantly, Siebenmann et al. 
(2013) and the current study were performed at 3454 m and 3800 m, respectively, which is a 
relatively low altitude compared to 5260 m in the work of Calbet and colleagues. The much 
higher elevation would elicit a greater pulmonary vasoconstriction than observed in the current 
study, and pulmonary vascular resistance may therefore play a more substantial role in limiting 
LV filling at higher altitude and render the impact of hypovolemia relatively inconsequential.  
 
In the current study, the reversal of hypoxic pulmonary vasoconstriction at high altitude led to 
there being no statistically significant difference in LV EDV and SV compared to sea level. 
However, given that probability values of there being a significant difference were close to 
achieving significance, and effect sizes suggest there was a meaningful difference between sea 
level and HA-SIL, reversal of hypoxic pulmonary vasoconstriction may not have been as 
effective in normalising LV EDV and SV as plasma volume expansion. Curiously, LV EDV and SV 
were lower in the HA-PVX-SIL trial compared to HA-PVX, despite the same volume 
normalisation protocol. This latter observation may be explained by the systemic vasodilatory 
effects of Sildenafil (Vardi et al., 2002), resulting in a greater volume being required within the 
systemic circulation to maintain the same blood pressure. This would mean the volume infused 
in the HA-PVX-SIL trial would not necessarily present as an enhanced cardiac filling. Despite a 
reduction in stroke volume, we did not observe any decrement in right ventricular function 
upon ascent to high altitude. This is in contrast to previous measurements we have taken above 
5000 m (Stembridge et al., 2014), differences that might be related to the smaller increase in 
pulmonary artery systolic pressure observed in the current study at 3800 m (+32%) compared 
to 5050 m (+43%).  
 
Whilst both plasma volume expansion and reversal of hypoxic pulmonary vasoconstriction 
increased LV filling, the increase in LV EDV was smaller with the reversal of hypoxic pulmonary 
vasoconstriction compared to plasma volume expansion. This suggests that the reduction in 
plasma volume may have a greater effect on LV filling at 3800 m compared to the increase in 
pulmonary vascular resistance. Interestingly, when plasma volume expansion and Sildenafil 
were combined, there was no additive effect. However, given the volume infused was intended 
to match sea level blood volume, and the pharmacological intervention lowered pulmonary 
vascular resistance towards but not below sea level values, there is no reason why LV EDV 
would increase beyond values recorded at sea level. Collectively, our findings and those from 
previous investigations suggest that both hypovolemia and hypoxic pulmonary vasoconstriction 
decrease LV filling and ejection, but hypoxic pulmonary vasoconstriction may play a greater role 
at more extreme altitudes.  
 
Restoration of left ventricular filling but persistent changes in left ventricular mechanics 
 
A number of recent studies have reported an increase in LV twist at high altitude (Stembridge et 
al., 2014; Dedobbeleer et al., 2015; Osculati et al., 2015; Maufrais et al., 2016). In our previous 
work (Stembridge et al., 2015), we hypothesised that the increase in LV twist may be a 
consequence of the decrease in LV filling observed upon ascent to high altitude. In contrast to 
our hypothesis, restoring LV EDV in the current study had no effect on LV twist suggesting an 
alternative mechanism(s) for the elevation of LV mechanics at high altitude. Osculati et al. 
(2016) have proposed that the increase in LV twist is directly related to subendocardial 
dysfunction. This has yet to be experimentally investigated, but it is unlikely that the degree of 
hypoxemia experienced in our healthy subjects would be sufficient to impair myocardial 
function and increase twist. More likely, is the effects of enhanced inotropic and chronotropic 
stimulation on LV twist, as circulating catecholamine’s are known to be increased at high 
altitude (Mazzeo & Reeves, 2003) and have been shown to substantially increase LV twist (Dong 
et al., 1999). As such, careful follow-up experimental investigation is required to delineate these 
mechanisms.  
 
Hypovolemia and Hypoxic pulmonary vasoconstriction as a limiting factor to exercise capacity 
 
Both the reversal of hypoxic pulmonary vasoconstriction and the restoration of plasma volume 
have been shown to increase exercise capacity at high altitude (Robach et al., 2000; Ghofrani et 
al., 2004; Faoro et al., 2009; Naeije et al., 2010), although this is not a universal finding (Calbet et 
al., 2004; Fischler et al., 2009). We observed no effect of plasma volume expansion or reduction 
in pulmonary vascular resistance on maximal exercise capacity in our cohort. Previous studies 
that have demonstrated the reversal of hypoxic pulmonary vasoconstriction to have a beneficial 
effect on exercise performance have been performed under more severe normobaric (FiO2 0.10-
0.12) and hypobaric (5050-5245 m) hypoxia (Ghofrani et al., 2004; Faoro et al., 2009; Naeije et 
al., 2010) than used in the current study. As such, similar to LV filling, hypoxic vasoconstriction 
may play a much greater role in limiting exercise capacity at altitudes above 5000 m. Thus, 
pharmacological strategies to increase exercise performance at high altitude may only be 
worthwhile when the athlete or mountaineer reaches a threshold altitude likely to be above 
4500-5000 m.   
 
Limitations 
 
Due to the inherent risks, we were not able to directly assess the pulmonary hemodynamic 
responses to high attitude at rest or during exercise. However, in using echocardiography, we 
chose a technique that is recommended for the clinical assessment of the pulmonary 
vasculature (Rudski et al., 2010) and shows good agreement with invasive measures (Yock & 
Popp, 1984; Currie et al., 1985). Additionally, our cohort is relatively small and that may 
potentially have led to a type II error. Due to logistical issues associated with field work in 
remote locations, high altitude studies seldom report data on large cohorts (Ainslie, 2014). 
However, in support of our data, power analyses were completed a priori based on effect sizes 
for Hb concentration, LV EDV and PASP from previous work (Stembridge et al., 2014) and they 
demonstrated that we needed n=8 as a minimum required sample size to detect a statistically 
significant effect with alpha set to 0.05 based on a 95% chance of a statistically significant 
outcome. Notwithstanding, some of the measures we report are associated with a higher degree 
of variability (e.g. right ventricular areas), and this may explain why no significant differences 
were not observed in these measures. 
 
By design, we chose to match absolute workload between conditions as cardiac output is known 
to be the same for a given power output at sea level and following 3-5 day at high altitude. 
However, caution must be exercised when interpreting our data, as the higher relative workload 
will mean our indices of cardiac function were recorded at 50% of peak power at sea level, but 
56% and 57% of peak power in the HA-PVX and HA-PVX-SIL trials, respectively.  This may 
therefore overestimate the cardiac response to submaximal exercise at high altitude. As stated 
in the methods, due to an electrical fault approximately half of the high altitude testing was 
performed on a different Lode ergometer. However, as the bike was from the same 
manufacturer and had undergone the same calibration procedures, and the order of visits were 
randomised, we are confident that this will not have affected the outcomes of the study. We 
acknowledge that some of the saline infused will leave the vascular compartment. However, 
following the infusion Hb concentration and haematocrit were checked to ensure a plasma 
volume expansion had been achieved. Lastly, this study only recruited male participants, as it 
would not have been possible to match testing days to specific periods of the menstrual cycle 
given that the experimental design required six visits over a 22-day period. This is particularly 
relevant to our study, as chemoreflex stimulation is known to vary depending on menstrual 
phase (Muza et al., 2001; Usselman et al., 2013). Unfortunately, this is an unavoidable issue with 
field testing and may therefore limit the broad applicability of our results to the general 
population.  
 
 
Conclusion 
 
In summary, this study demonstrates that both plasma volume and hypoxic pulmonary 
vasoconstriction play a role in regulating LV filling during sojourn to 3800 m above sea level. 
However, at 3800 m the decrease in plasma volume appears to dominate over the increase in 
pulmonary vascular resistance, and there is no additive effect when plasma volume is 
normalised and hypoxic pulmonary vasoconstriction is reversed. In contrast to LV filling, there 
is no role of hypovolemia or hypoxic pulmonary vasoconstriction in limiting exercise capacity at 
moderate-high altitude which may suggest the existence of a “threshold altitude” where by 
pharmacological strategies to improve exercise capacity at high altitude via administration of 
pulmonary vasodilators may only worthwhile at more extreme altitudes.   
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Table 1- Haematological, pulmonary hemodynamic and systemic hemodynamic responses to high altitude, plasma volume expansion and 
sildenafil administration  
                      
    
SL (244 
m) 
  High Altitude (3800 m)   
    Baseline   HA HA-PVX ANOVA   HA-SIL HA-PVX-SIL ANOVA 
Haematological                   
  SpO2 (%) 98 ± 1   89 ± 3*** (6.088) 90 ± 2*** (5.234) <0.001   89 ± 2*** (5.682) 89 ± 1*** (9.686) <0.001 
  Hb Concentration (g dl-1) 148 ± 5   160 ± 6** (2.256) 148 ± 3 (0.084) <0.001   157 ± 8*** (1.443) 147 ± 7 (0.112) <0.001 
  Haematocrit (%) 44 ± 2   47 ± 2** (1.161) 44 ± 2 (0.205) <0.001   47 ± 3** (0.946) 44 ± 2 (0.205) <0.001 
  Plasma Volume (ml) 
3709 ± 
573 
  - -     - -   
  Blood Volume (ml) 
6249 ± 
925 
  - -     - -   
  % Change BV vs. baseline -   -6 ± 5** 0.2 ± 3.5 <0.001   -7 ± 4*** 0.4 ± 3.6 <0.001 
  % Change PV vs. baseline -   -11 ± 7** 0.4 ± 7 <0.001   -12 ± 7*** 1.3 ± 6.3 <0.001 
Pulmonary Vascular                   
  PASP (mmHg) 19.6 ± 4.3   26.0 ± 5.4* (1.331) 25.8 ± 5.1* (1.316) <0.001   22.1 ± 3.9 (0.569) 21.2 ± 3.3 (0.423) P=0.310 
  PVR (Woods units) 
1.21 ± 
0.14 
  1.51 ± 0.25* (1.544) 1.54 ± 0.20* (1.950) P=0.007   1.37 ± 0.26 (0.807) 1.30 ± 0.12 (0679) P=0.130 
Systemic Vascular                   
  Systolic Blood Pressure 133 ± 16   142 ± 17 (0.618) 139 ± 12 (0.454) P=0.233   136 ± 15 (0.219) 140 ± 13 (0.502) P=0.376 
  Diastolic Blood Pressure 75 ± 13   81 ± 9 (0.567) 82 ± 11 (0.621) P=0.262   81 ± 9 (0.593) 85 ± 13 (0.803) P=0.106 
                      
 
SpO2, peripheral oxygen saturation; Hb, haemoglobin; BV, blood volume; PV, plasma volume; PASP, pulmonary artery systolic pressure; PVR, 
pulmonary vascular resistance. Data are reported as mean ± SD (Cohen’s d).   *= P<0.05, **=P<0.01 and ***=P<0.001 all compared to sea level.  
  
Table 2- Left and right ventricular function responses to high altitude, plasma volume expansion and sildenafil administration 
                      
   SL (244 m)   High Altitude (3800 m)     
  Baseline   HA HA-PVX ANOVA   HA-SIL HA-PVX-SIL ANOVA   
                    
Transmitral E (ms-1) 0.92 ± 0.12   0.81 ± 0.17** (0.755) 0.87 ± 0.15 (0.347) P=0.003   0.81 ± 0.15* (0.826) 0.80 ± 0.15* (0.844) P=0.006   
Transmitral A (ms-1) 0.39 ± 0.05   0.42 ± 0.08 (0.600) 0.40 ± 0.08 (0.174) P=0.128   0.40 ± 0.06 (0.239) 0.42 ± 0.10 (0.445) P=0.369   
Transmitral E/A Ratio 2.41 ± 0.37   1.93 ± 0.33** (1.392) 2.24 ± 0.41 (0.422) P<0.01   2.07 ± 0.47* (0.810) 2.01 ± 0.58* (0.843) P=0.013   
LV Twist (°) 15.9 ± 4.0   19.4 ± 6.1* (0.697) 19.5 ± 6.2* (0.697) P<0.05   19.2 ± 9.6 (0.484) 18.2 ± 7.1 (0.411) P=0.231   
Systolic Twist Velocity (° s-1) 107 ± 18   140 ± 28** (1.405) 132 ± 24* (1.190) P=0.002   125 ± 41 (0.620) 135 ± 31 (1.142) P=0.065   
Untwisting Velocity (° s-1) 107 ± 26   127 ± 39 (0.594) 120 ± 20 (0.555) P=0.143   125 ± 48 (0.475) 116 ± 34 (0.285) P=0.278   
Basal Rotation (°) 5.4 ± 2.2   6.4 ± 3.5 (0.353) 5.4 ± 2.1 (0.003) P=0.357   6.7 ± 3.6 (0.451) 5.7 ± 2.7 (0.122) P=0.179   
Apical Rotation (°) 11.5 ± 4.3   14.7 ± 4.8* (0.724) 14.9 ± 5.5 (0.709) P=0.038   13.7 ± 7.1 (0.395) 13.5 ± 5.9 (0.407) P=0.317   
Basal Circumferential Strain (%) 19.5 ± 1.7   21.1± 3.5 (0.623) 19.3 ± 3.4 (0.051) P=0.198   20.0  ± 3.25 (0.214) 20.6 ± 3.0 (0.459) P=0.445   
Basal Circumferential Strain Rate (%-1) 1.12 ± 0.13   1.32 ± 0.26 (1.010) 1.32 ± 0.26 (0.657) P=0.062   1.23 ± 0.22 (0.608) 1.24 ± 0.29 (0.537) P=0.180   
Apical Circumferential Strain (%) 26.6 ± 5.1   27.6 ± 5.2 (0.191) 26.7 ± 5.2 (0.018) P=0.518   27.8 ± 0.64 (0.236) 27.8 ± 5.3 (0.233) P=0.314   
Apical Circumferential Strain Rate (%-1) 1.62 ± 0.42   1.99 ± 0.46*** (0.844) 1.86 ± 0.44** (0.562) P<0.001   2.14 ± 0.64** (0.994) 1.95 ± 0.59** (0.655) P=0.002   
LV Longitudinal Strain (%) 19.4 ± 1.2   19.7 ± 2.8 (0.144) 20.0 ± 1.8 (0.426) P=0.672   19.5 ± 1.9 (0.033) 19.0 ± 1.9 (0.261) P=0.215   
LV Longitudinal Strain Rate (%-1) 0.99 ± 0.11   1.17 ± 0.16 (1.328) 1.06 ± 0.09 (0.719) P=0.027   1.11 ± 0.22 (0.738) 1.07 ± 0.14 (0.612) P=0.196   
                    
End Diastolic Area (cm2) 23.7 ± 3.7   21.0 ± 2.5 (0.881) 23.5 ± 2.9 (0.078) P=0.045   21.5 ± 3.0 (0.666) 21.6 ± 3.3 (0.612) P=0.060   
End Systolic Area (cm2) 13.3 ± 2.1   11.4 ± 2.8 (0.784) 12.2 ± 2.3 (0.493) P=0.038   12.7 ± 2.6 (0.288) 12.0 ± 2.6 (0.572) P=0.150   
Fractional Area Change (%) 43.6 ± 5.5   45.7 ± 11.7 (0.245) 47.9 ± 7.3 (0.668) P=0.478   41.0 ± 8.7 (0.358) 44.7 ± 4.8 (0.214) P=0.299   
Transtricuspid E (ms-1) 0.60 ± 0.08   0.53 ± 0.06 (0.881) 0.57 ± 0.06 (0.367) P=0.271   0.52 ± 0.03 (1.219) 0.52 ± 0.18 (0.553) P=0.469   
Transtricuspid A (ms-1) 0.35 ± 0.09   0.33 ± 0.03(0.302) 0.30 ± 0.07 (0.703) P=0.490   0.33 ± 0.04 (0.341) 0.36 ± 0.18 (0.035) P=0.696   
Transtricuspid E/A Ratio 1.78 ± 0.47   1.61 ± 0.23 (0.477) 2.03 ± 0.54 (0.492) P=0.542   1.61 ± 0.20 (0.510) 1.67 ± 0.63 (0.208) P=0.719   
RV Longitudinal Strain (%) 23.2 ± 1.8   23.9 ± 2.9 (0.318) 23.0 ± 3.2 (0.050) P=0.510   23.3 ± 2.5 (0.069) 24.3 ± 2.2 (0.559) P=0.303   
RV Longitudinal Strain Rate (%-1) 1.16 ± 0.22   1.31 ± 0.21 (0.716) 1.19 ± 0.12 (0.177) P=0.161   1.21 ± 0.2 (0.248) 1.25 ± 0.19 (0.468) P=0.363   
                      
E, early filling; A, late filling; LV, left ventricular. Data are reported as mean ± SD (Cohen’s d). *= P<0.05, **=P<0.01 and ***=P<0.001 all compared to 
sea level.   
Figure 1- An overview of the experimental design for both the sea level and high altitude 
protocols.  
 
Figure 2- Left ventricular filling and ejection during rest at sea level (SL) and at high 
altitude (HA) following plasma volume expansion (HA-PVX), with sildenafil 
administration (HA-SIL) and combined plasma volume expansion and sildenafil 
administration (HA-PVX-SIL). Statistical significance reported on the figures are from the two 
separate one-way analysis of variance tests run to compare SL with HA and HA-PVX and SL with 
HA-SIL and HA-PVX-SIL. P values in the smaller font refer to the post hoc tests where each 
condition was compared to sea level, and effect sizes (Cohen’s d) and 5-95% confidence 
intervals (CI) are also reported.  
 
Figure 3- Left ventricular filling and ejection during 50% peak power supine cycling sea 
level (SL) and at high altitude (HA) following plasma volume expansion (HA-PVX), with 
sildenafil administration (HA-SIL) and combined plasma volume expansion and sildenafil 
administration (HA-PVX-SIL). Statistical significance reported on the figures are from the two 
separate two-way analysis of variance tests run to compare SL with HA and HA-PVX and SL with 
HA-SIL and HA-PVX-SIL. P values are reported for Condition and Exercise (e.g. 0 to 50% power), 
and effect sizes (Cohen’s d) are also reported.  
 
Figure 4- Maximal oxygen consumption (VO22 peak) and peak power achieve during the 
incremental tests to exhaustion at sea level (SL) and at high altitude (HA) following 
plasma volume expansion (HA-PVX) and combined plasma volume expansion and 
sildenafil administration (HA-PVX-SIL). Statistical significance reported on the figures are 
from a one-way analysis of variance tests run to compare SL with HA, HA-PVX and HA-PVX-SIL, 
with effect sizes (Cohen’s d) and 5-95% confidence intervals (CI) are also reported. 
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